Latest Corporate News

GLATECT(TM) is now covered by five provincial drug plans

GLATECTTM (glatiramer acetate injection, 20 mg/1 mL) is now the only glatiramer-based treatment covered by five provincial drug plans for patients new to glatiramer acetate for the treatment of relapsing-remitting multiple sclerosis (RRMS) GLATECT(TM) is now covered for all patients new to glatiramer acetate by the provincial drug plans in Quebec, Alberta, Saskatchewan, Manitoba and New Brunswick, based on specific criteria for the treatment of relapsing-remitting multiple sclerosis (RRMS). GLATECT(TM) is the first subsequent glatiramer-based treatment to the original glatiramer acetate (COPAXONE®). GLATECTTM becomes the first subsequent glatiramer-based treatment in Multiple Sclerosis (MS) available for reimbursement under Canadian public drug plans.

 

The Pharmascience Team met the Enbridge Ride to Conquer Cancer Challenge and raised funds to advance cancer research

 

Pharmascience Inc launches (Pr)pms-TRANDOLAPRIL, first generic bioequivalent to (Pr)MAVIK available on the market, for the treatment of mild to moderate essential hypertension